

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9939)

**CHANGE OF JOINT COMPANY SECRETARY
AND AUTHORIZED REPRESENTATIVE
AND**

**WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE
LISTING RULES**

CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE

The board of directors (the “**Board**”) of Kintor Pharmaceutical Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) announces that Ms. Wing Han Sharon LEUNG (“**Ms. Leung**”) has tendered her resignation as the joint company secretary of the Company (the “**Joint Company Secretary**”) and an authorized representative of the Company (the “**Authorized Representative**”) under the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) with effect from 17 February 2022.

Ms. Leung confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board further announces that Mr. Wai Chiu WONG (“**Mr. Wong**”) has been appointed as a Joint Company Secretary and the Authorized Representative with effect from 17 February 2022.

The biographical details of Mr. Wong and Ms. Yan LU (“**Ms. Lu**”), the other Joint Company Secretary of the Company, are set out as follows:

Mr. Wong is the Associate Director of SWCS Corporate Services Group (Hong Kong) Limited. Mr. Wong has extensive experience in compliance and listed companies secretarial work.

Mr. Wong is a fellow of Hong Kong Chartered Governance Institute (previously known as Hong Kong Institute of Chartered Secretaries), a fellow of the Chartered Governance Institute, a member of CPA Australia, a member of the Hong Kong Trustee Association and a Certified Trust Practitioner.

Mr. Wong possesses a B. Soc. Sc. (Hon.) from the University of Hong Kong, a Post-Graduate diploma in Hong Kong and United Kingdom law from the Manchester Metropolitan University in

the United Kingdom, Master degree in Corporate Governance from the Hong Kong Polytechnic University, Master Degree in Arbitration and Dispute Resolution from City University of Hong Kong and Master of Applied Science Degree from the University of Technology, Sydney, Australia.

Ms. Lu, aged 39, was appointed as the Chief Financial Officer of the Group in December 2019 and a joint company secretary of the Company in November 2021. She was further appointed to be an executive director of the Company on 31 January 2022. Ms. Lu is primarily responsible for financial internal control, investor relations, public relations and treasury management of the Group. Prior to joining the Group, Ms. Lu has over 13 years of experience in investment banking business. Ms. Lu joined GF Capital (Hong Kong) Limited in July 2018 with her last position as the director, head of investment banking business and managing director. From September 2007 to July 2018, Ms. Lu worked at UBS Securities Hong Kong Limited with her last position as an executive director in the Asian healthcare group. She has been a signing Principal for Hong Kong initial public offerings (IPO) since 2014. Ms. Lu obtained her master's degree in finance from Guanghua School of Management in Peking University (北京大學), and her bachelor's degree in finance in Renmin University of China (中國人民大學).

WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Reference is made to the waiver (the “**Waiver**”) granted to the Company by the Stock Exchange from strict compliance with the requirements of Rules 3.28 and 8.17 of the Listing Rules in respect of the eligibility of Ms. Lu to act as a Joint Company Secretary for a three-year period from the date of appointment of Ms. Lu as a Joint Company Secretary of the Company (i.e. 26 November 2021) to 25 November 2024 (the “**Waiver Period**”), on the condition that Ms. Lu would be assisted by Ms. Leung, who possesses the qualifications required under Rule 3.28 of the Listing Rules, during the Waiver Period. Relevant details of the Waiver were disclosed in the announcement of the Company dated 26 November 2021.

Given the condition of the Waiver could no longer be fulfilled following the resignation of Ms. Leung, the Company has applied to the Stock Exchange and has already been granted with a new waiver (the “**New Waiver**”) by the Stock Exchange from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for the remaining period of the Waiver Period (i.e. from 17 February 2022 to 25 November 2024) (the “**New Waiver Period**”) in relation to the eligibility of Ms. Lu to act as a Joint Company Secretary, on the conditions that:

- i. Ms. Lu will be assisted by Mr. Wong during the New Waiver Period;
- ii. the New Waiver could be revoked if there are material breaches of the Listing Rules by the Company; and
- iii. the Company will announce the reasons for, and the details and conditions of the New Waiver, and the qualification and experience of both Mr. Wong and Ms. Lu.

The publication of this announcement aims to satisfy condition (iii) set out above.

Before the end of the New Waiver Period, the Company must demonstrate and seek confirmation from the Stock Exchange that Ms. Lu, having had the benefit of Mr. Wong's assistance during the New Waiver Period, has attained the relevant experience and is capable of discharging the functions of company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary. The New Waiver will be revoked immediately if and when Mr. Wong ceases to be a Joint Company Secretary.

The Board would like to take this opportunity to express its gratitude to Ms. Leung for her valuable contribution to the Company during her tenure of service, and to welcome Mr. Wong on his new appointment.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
*Chairman of the Board, Executive Director and
Chief Executive Officer*

Hong Kong, 18 February 2022

As of the date of this announcement, the executive Directors are Dr. Youzhi Tong and Ms. Yan Lu; the non-executive Directors are Mr. Weipeng Gao, Dr. Yan Wang and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

** For identification purpose only*